Issue 170

23.10.2020

Europe
USA
Latam & Caribbean
APAC
Africa & Middle East

Highlights

 

NEW REPORT EXAMINES THE IMPACT OF CANNABIS ON PHARMACEUTICAL INDUSTRY

The rapid growth of cannabis-based medicines is becoming a significant disruptor of the global pharmaceutical industry, but the point of entry has been complicated by the historic scheduling of cannabis as a schedule 1 narcotic.

However, pharmaceutical cannabis products such as Epidyolex, Sativex and Dronabinol have become serious alternatives to traditional pharmaceuticals and are beginning to shift how the pharma industry approaches cannabis.

The Pharmaceutical Cannabis Report is now available both in digital and print versions for purchase.

 

ACCESS NOW

HIGHLIGHTS 

Europe

 

CANNABIS EUROPA RETURNS TO PROHIBITION PARTNERS LIVE

 

Cannabis Europa makes a timely return to Prohibition Partners LIVE next month.

Between 17-20 November, European business leaders & policymakers will converge virtually to help shape the future of cannabis.

Early Bird Tickets (£115 / €127) includes four-day event access.

 

LEARN MORE

USA

 

CANXCHANGE

 

Canada

 

Latam & Caribbean

 

APAC

 

Africa & Middle East